# NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

> **NCT01591551** · PHASE4 · COMPLETED · sponsor: **Cornerstone Health Care, PA** · enrollment: 37 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Natalizumab (Tysabri)

## Key facts

- **NCT ID:** NCT01591551
- **Lead sponsor:** Cornerstone Health Care, PA
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01591551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01591551, "NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01591551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*